ArticlePloS one2025
Long-term pulmonary sequelae and convalescent immune reactions in mild to moderate COVID-19 patients during the active treatment era.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung ultrasound alterations six months after COVID-19 pneumonia: a descriptive study.BMC pulmonary medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the COVID-19 endemic phase, pulmonary sequelae substantially contributed to disease burden. Immunologic responses may be critical in both acute COVID-19 and in long-term sequelae. We aimed to evaluate associations between convalescent neutralizing antibodies and long-term pulmonary sequelae in patients hospitalized with mild to moderate COVID-19.
methodsAmong patients who recovered from hospitalization due to COVID-19, those who consented to participate in the study provided convalescent serum between June 2021 and April 2022. These baseline patients were invited for a second follow-up visit between September and November 2023. A serum sample was collected at the second visit, and low-dose chest computed tomography (CT) was performed. Pulmonary sequelae were defined as findings of fibrotic, fibrotic-like, and ground-glass opacities (GGOs). Antibody and cytokine levels were assessed in serum samples from the baseline convalescent phase, and antibody levels were also measured in the serum sample at the second visit.
resultsA total of 107 patients were enrolled at baseline, and 37 consented to the second follow-up visit. Most second-visit patients (97.3%, 36/37) did not require an oxygen supply beyond that provided via masks or nasal prongs. Twenty-two patients (59.5%) exhibited pulmonary sequelae on chest CT at a median follow-up period of 27 months (interquartile range 25-28, range 22-30) after hospitalization for COVID-19. Fifteen patients (40.5%) had fibrotic or fibrotic-like pulmonary changes, and twelve (32.4%) had GGOs. Pulmonary sequelae were associated with older age (adjusted odds ratio 1.130, 95% confidence interval 1.028-1.243; P = 0.011). There were no significant differences in convalescent cytokines or neutralizing antibodies between patients with pulmonary sequelae and those without.
conclusionPulmonary sequelae were quite common on chest CT after two years of mild to moderate COVID-19 and were associated with older age. The immunological or inflammatory status in the immediate post-acute infection period did not predict long-term complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.